345859 <common-name>2-[(3z)-3-[3-[(2-chlorophenyl)methyl]-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene]-2-oxoindol-1-yl]-n-(4-methylphenyl)acetamide</common-name> <description>2-[(3z)-3-[3-[(2-chlorophenyl)methyl]-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene]-2-oxoindol-1-yl]-n-(4-methylphenyl)acetamide is a chemical compound with the formula C27H20ClN3O3S2. With an average molecular weight of 534.10 g/mol, 2-[(3z)-3-[3-[(2-chlorophenyl)methyl]-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene]-2-oxoindol-1-yl]-n-(4-methylphenyl)acetamide is a heavy molecule.</description> <cas nil="true"/> <pubchem-id>5895384</pubchem-id> <chemical-formula>C27H20ClN3O3S2</chemical-formula> <weight>534.1</weight> <appearance nil="true"/> <melting-point nil="true"/> <boiling-point nil="true"/> <density nil="true"/> <solubility nil="true"/> <specific-gravity nil="true"/> <flash-point nil="true"/> <vapour-pressure nil="true"/> <route-of-exposure nil="true"/> <target nil="true"/> <mechanism-of-toxicity nil="true"/> <metabolism nil="true"/> <toxicity nil="true"/> <lethaldose nil="true"/> <carcinogenicity nil="true"/> <use-source nil="true"/> <min-risk-level nil="true"/> <health-effects nil="true"/> <symptoms nil="true"/> <treatment nil="true"/> <created-at type="dateTime">2026-08-31T08:52:30Z</created-at> <updated-at type="dateTime">2026-08-31T08:52:30Z</updated-at> <interacting-proteins nil="true"/> <wikipedia nil="true"/> <uniprot-id nil="true"/> <kegg-compound-id nil="true"/> <omim-id nil="true"/> <chebi-id nil="true"/> <biocyc-id nil="true"/> <ctd-id nil="true"/> <stitch-id nil="true"/> <drugbank-id nil="true"/> <pdb-id nil="true"/> <actor-id nil="true"/> <organism nil="true"/> <export type="boolean">true</export> <metabolizing-proteins nil="true"/> <transporting-proteins nil="true"/> <moldb-smiles>CC1=CC=C(C=C1)NC(=O)CN2C3=CC=CC=C3C(=C4C(=O)N(C(=S)S4)CC5=CC=CC=C5Cl)C2=O</moldb-smiles> <moldb-formula>C27H20ClN3O3S2</moldb-formula> <moldb-inchi>InChI=1S/C27H20ClN3O3S2/c1-16-10-12-18(13-11-16)29-22(32)15-30-21-9-5-3-7-19(21)23(25(30)33)24-26(34)31(27(35)36-24)14-17-6-2-4-8-20(17)28/h2-13H,14-15H2,1H3,(H,29,32)/b24-23-</moldb-inchi> <moldb-inchikey>TWEXFPWZUXKHCR-VHXPQNKSSA-N</moldb-inchikey> <moldb-average-mass type="decimal" nil="true"/> <moldb-mono-mass type="decimal">533.0634615</moldb-mono-mass> <origin nil="true"/> <state nil="true"/> <logp>5.3</logp> <hmdb-id nil="true"/> <chembl-id nil="true"/> <chemspider-id nil="true"/> <structure-image-file-name nil="true"/> <structure-image-content-type nil="true"/> <structure-image-file-size type="integer" nil="true"/> <structure-image-updated-at type="dateTime" nil="true"/> <biodb-id nil="true"/> <synthesis-reference nil="true"/> <structure-image-caption nil="true"/> <chemdb-id>CHEM341752</chemdb-id> <dsstox-id nil="true"/> <toxcast-id nil="true"/> <stoff-ident-origin nil="true"/> <stoff-ident-id nil="true"/> <susdat-id nil="true"/> <iupac>2-[(3z)-3-[3-[(2-chlorophenyl)methyl]-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene]-2-oxoindol-1-yl]-n-(4-methylphenyl)acetamide</iupac> <moldb-polar-surface-area nil="true"/> <moldb-refractivity nil="true"/> <moldb-polarizability nil="true"/> <moldb-rotatable-bond-count nil="true"/> <moldb-acceptor-count nil="true"/> <moldb-donor-count nil="true"/> <moldb-pka-strongest-acidic nil="true"/> <moldb-pka-strongest-basic nil="true"/> <moldb-physiological-charge nil="true"/> <moldb-number-of-rings nil="true"/> <moldb-alogps-logp nil="true"/> <moldb-alogps-logs nil="true"/> <moldb-alogps-solubility nil="true"/> <kingdom>Organic compounds</kingdom> <superklass>Organic acids and derivatives</superklass> <klass>Carboxylic acids and derivatives</klass> <subklass>Amino acids, peptides, and analogues</subklass> <paper-count type="integer" nil="true"/> <sync-id>CED0296213</sync-id> <structure-inchikey>TWEXFPWZUXKHCR-UHFFFAOYSA-N</structure-inchikey> <structure-fingerprint>4000020000800040000000000000000000000100000000001000000000000001000020000000008002000000000000000000000000000000000000000000000000400000080000000000000020000010000000000000000000000000000000011000000010000000010000040000000100100000020080000000000000000040000400800000000000000080000000000100000000000000000080080100008000400004000000080000000000000020000000000000000000000000100000000000244001000000810000000010000000042000000200040000000000008100000000000040000000800680000000000000000300000000000008</structure-fingerprint> <structure-pattern-fingerprint>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</structure-pattern-fingerprint> <structure-pickle type="binary" encoding="base64">776t3gAAAAAQAAAAAwAAAAAAAAAkAAAAKAAAAIABBgBgAAAAAQMGQCgAAAAD BAZAaAAAAAMDAQZAaAAAAAMDAQZAKAAAAAMEBkBoAAAAAwMBBkBoAAAAAwMB BwBoAAAAAwIBBgAoAAAAAwQIACgAAAADAgYAYAAAAAICBwAoAAAAAwMGQCgA AAADBAZAaAAAAAMDAQZAaAAAAAMDAQZAaAAAAAMDAQZAaAAAAAMDAQZAKAAA AAMEBgAoAAAAAwQGACgAAAADBAYAKAAAAAMECAAoAAAAAwIHACgAAAADAwYA KAAAAAMEEAAoAAAAAwIQACAAAAACBgBgAAAAAgIGQCgAAAADBAZAaAAAAAMD AQZAaAAAAAMDAQZAaAAAAAMDAQZAaAAAAAMDAQZAKAAAAAMEEQAgAAAAAQYA KAAAAAMECAAoAAAAAwILAAEAAQJoDAIDaAwDBGgMBAVoDAUGaAwEByAHCCAI CSgCCAoACgsACwwgDA1oDA0OaAwOD2gMDxBoDBARaAwREiASEygCExQgFBUo AhQWIBYXIBcYKAIXGQAWGgAaGwAbHGgMHB1oDB0eaAweH2gMHyBoDCAhABIi ICIjKAIGAWgMIgsgEQxoDBkTACAbaAxCBQAAAAYBBgUEAwIGDQ4PEBEMBRQT GRcWBhwdHh8gGwUiEhEMCxcEAAAAAAAAABY= </structure-pickle> <structure-indexed-at type="dateTime">2026-09-19T05:44:46Z</structure-indexed-at> </compound>